References
1. Bartlett AW, Cann MP, Yeoh DK, Bernard A, Ryan AL, Blyth CC, et al. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national,10 year review. Pediatr Blood Cancer. 2019;66(4):e27564.
2. Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Bruggemann RJ. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clinical pharmacokinetics. 2018;57(3):267-86.
3. Groll AH. Efficacy and safety of antifungals in pediatric patients. Early human development. 2011;87 Suppl 1:S71-4.
4. Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433-44.
5. Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. The Journal of antimicrobial chemotherapy. 2018;73(12):3221-30.
6. García Morin M, Cela E, Garrido C, et al. Trasplante de médula ósea en pacientes con anemia falciforme. Experiencia en un centro [Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre]. An Pediatr (Barc). 2017;86(3):142-150.
7. Noè A, Cappelli B, Biffi A, et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr . 2010;36:14.
8. Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548-56.
9. Paciaroni K, De Angelis G, Gallucci C, Alfieri C, Ribersani M, Roveda A, et al. Invasive pulmonary aspergillosis in a haematopoietic stem cell transplant recipient with sickle cell disease: a successful treatment. Mediterr J Hematol Infect Dis . 2015;7(1):e2015006.
10. Goussetis E, Efstathiou E, Paisiou A, Avgerinou G, Zisaki K, Giamouris VJ, et al. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies. Transpl Infect Dis . 2015;17(2):201-207.
11. Al Otaibi FE. Fatal case of cerebral aspergilloma complicated by ventriculitis and bacteremia due to Salmonella species in a sickle cell disease patient. Saudi Med J . 2018;39(9):935-939.
12. Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant . 2019;54(10):1575-1585.
13. Gonzalo Pascual H, Ponce Salas B, Rincón López EM, Santiago García B, Garrido Colino C, Hernández-Sampelayo Matos T. Infección fúngica invasora en pacientes hematooncológicos: revisión de 10 años. Communication poster presented in VIII Congress of the Spanish Society of Pediatric Infectology (SEIP) and VII Hispano-Mexican Meeting of Pediatric Infectious Diseases. 2016 Mar 3-5; Valencia, Spain.
14. Molina JR, Serrano J, Sanchez-Garcia J, Rodriguez-Villa A, Gomez P, Tallon D, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marrow Transplant . 2012;47(4):562-567.
15. Gwee A, Cranswick N, Curtis N. Posaconazole: promising but problematic in practice in pediatric patients. Pediatr Infect Dis J . 2015;34(6):604-606.
16. Heinz WJ, Cabanillas Stanchi KM, Klinker H, et al. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Med Mycol . 2016;54(2):128-137.
17. Kobayashi C, Hanadate T, Niwa T, Yoshiyasu T, So M, Matsui K. Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study. J Pediatr Hematol Oncol . 2015;37(5):e285-e291.
18. Viscoli C, Bassetti M, Castagnola E, et al. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infect Dis . 2014;14:725.
19. Kotsopoulou M, Papadaki C, Anargyrou K, et al. Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study. Infect Dis Ther . 2019;8(2):255-268.
20. Albano E, Azie N, Roy M, Townsend R, Arrieta A. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation. J Pediatr Hematol Oncol . 2015;37(1):e45-e50.
21. Scott LJ. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients. Paediatr Drugs . 2017;19(1):81-90.
22. Bochennek K, Balan A, Müller-Scholden L, et al. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. J Antimicrob Chemother . 2015;70(5):1527-1530.
23. Chandra S, Fukuda T, Mizuno K, et al. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. J Antimicrob Chemother . 2018;73(6):1651-1658..
24. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother . 2007;51(10):3714-3719.
25. Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study [published correction appears in Biol Blood Marrow Transplant. 2011 Mar;17(3):441]. Biol Blood Marrow Transplant . 2010;16(10):1458-1462.
26. Neofytos D, Huang YT, Cheng K, Cohen N, Perales MA, Barker J, et al. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. Clin Infect Dis . 2015;61 Suppl 6(Suppl 6):S652-S661.
27. Manrique-Rodríguez S, Fernández-Llamazares CM. Standardization for safety: a feasible challenge. Farm Hosp. 2020 May 1;44(3):79-80.
28. Cangemi G, Barco S, Bandettini R, Castagnola E. Quantification of micafungin in human plasma by liquid chromatography-tandem mass spectrometry [published correction appears in Anal Bioanal Chem. 2014 May;406(13):3249]. Anal Bioanal Chem . 2014;406(6):1795-1798.
29. Institute NC. Common toxicity criteria version 3.0. Available at:http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_index.pdf (last accessed 22 July 2015).
30. Kim R, Koh Y, Shin DY, Choe PG, Kim NJ, Yoon SS, et al. The limited role of serum galactomannan assay in screening for invasive pulmonary aspergillosis in allogeneic stem cell transplantation recipients on micafungin prophylaxis: a retrospective study. Blood Res . 2017;52(4):300-306.
31. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis . 2008;46(12):1813-1821.
32. Muilwijk EW, Maertens JA, van der Velden W, Ter Heine R, Colbers A, Burger DM, et al. Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis. The Journal of antimicrobial chemotherapy. 2018;73(11):3095-101.
33. Chandra S, Fukuda T, Mizuno K, Davies SM, Teusink-Cross A Torin R, Marsh RA, Vinks A, Mehra P. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. J AntimicrobChemother 2018.
34. Funaki T, Miyairi I. Breakthrough Candidemia In Children On Micafungin. The Pediatric infectious disease journal. 2018;37(12):1258-60.
35. Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F, et al. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Annals of hematology. 2014;93(3):493-8.
36. Pfeiffer CD,  Garcia-Effron G,  Zaas AK,  Perfect JR,  Perlin DS, Alexander BD.Breakthrough invasive candidiasis in patients on micafungin,J Clin Microbiol,2010;48(7):2373-80.
37. Jean El Cheikh EC, Patrice C, Jean-Hugues D, ophieDucastelle-Leprêt D-L, Elsa D, Raoul H. Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France. Diagn Microbiol Infect Dis. 2019 Jul;94(3):268–73.
38. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0. 2018. Available from: http://www.eucast.org/clinical_breakpoints/.
39. Clinical and Laboratory Standards Institute . Reference method for broth dilution antifungal susceptibility testing of yeasts; 4thInformational Supplement. CLSI document M27-S4. Wayne: Clinical and Laboratory Standards Institute; 2012.
40. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol 2009; 47: 3323–5
41. Edwards AY, Skolnik JM, Dombrowsky E et al. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D:a report from the children’s oncology group. Cancer Chemother Pharmacol 2012; 70: 83–94.